Develops diagnostic tests for cancer, focusing on liquid biopsy technologies for early detection and monitoring.
OncoCyte Corporation is a leading molecular diagnostics company specializing in the research, development, and global commercialization of proprietary laboratory-developed tests designed for cancer detection. At the forefront of its innovative offerings is DetermaRx, a molecular test specifically tailored for early-stage adenocarcinoma of the lung. Additionally, the company has pioneered DetermaIO, a proprietary gene expression assay aimed at enhancing precision in immunotherapy treatment decisions. OncoCyte Corporation also provides comprehensive biomarker discovery testing, assay design and development, and clinical trial support services, catering to both healthcare providers and pharmaceutical companies seeking advanced diagnostic solutions.
Headquartered in Irvine, California, OncoCyte Corporation strategicaly positions itself within a vibrant biomedical hub known for pioneering research and technological innovation. The company's location provides access to a rich ecosystem of scientific expertise and collaborative opportunities, fostering ongoing advancements in cancer diagnostics. Through strategic collaborations, such as its partnership with Life Technologies Corporation, OncoCyte Corporation continues to expand its footprint in molecular diagnostics. This collaboration focuses on developing and commercializing the Oncomine Comprehensive Assay Plus and Determa IO assay, leveraging the Ion Torrent Genexus integrated sequencer and purification system to further enhance diagnostic accuracy and efficiency.
Driven by a commitment to improving patient outcomes and advancing cancer care, OncoCyte Corporation remains dedicated to pushing the boundaries of molecular diagnostics. With a robust portfolio of innovative tests and ongoing research initiatives, the company strives to empower clinicians with cutting-edge tools for early cancer detection and personalized treatment strategies, ultimately aiming to make a meaningful impact in the fight against cancer worldwide.